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Some of the most common and devastating disorders of the brain target the hippocampal formation. The
hippocampal formation is a complex circuit of interconnected regions, and it is assumed that clues into
the causes of these disorders are embedded within the circuit. Neuroimaging tools have been optimized
to interrogate the malfunctioning hippocampal circuit, and by applying these tools to patients in the earliest
stages of disease and to animal models, patterns of regional vulnerability have been established for
Alzheimer’s disease, schizophrenia, and cognitive aging. More recently, studies have begun deciphering
the cellular and molecular reasons underlying regional dysfunction. Collectively, this information clarifies
the pathophysiology of these disorders and informs on therapeutic strategies.Introduction
So deeply ingrained as to seem eternal, ‘‘anatomical localiza-
tion’’ is a relatively new concept in the annals of medicine. It is
easily forgotten that throughout most of the history of medicine,
diseases were thought to reflect diffuse processes caused by
imbalances of bodily substances or fluids. The shift toward
an anatomical basis of disease began slowly during the late
Renaissance and was only fully articulated in 1761 when the
anatomist Giovanni Morgagni published his textbook, ‘‘On the
Seats and Causes and Disease through an Investigation of
Anatomy’’ (Morgagni, 1761). This landmark textbook formulated
what subsequently became a first principle in modern medicine:
localizing the anatomical site of pathology is an important first
step toward better understanding, diagnosing, and, ultimately,
curing any disease. Cell theory and its medical offshoot ‘‘cellular
pathology,’’ pioneered by Rudolf Virchow (Virchow, 1863) and
others in the 19th century, refined the target of disease localiza-
tion. With the introduction of the idea that ‘‘sick cells’’ are the
basic unit of disease, localization needed to scale down from
an organ or structure to the level of afflicted cells.
Besides providing a basis for disease classification and
improving diagnostic accuracy, the ultimate promise of disease
localization is mechanistic. Answering why one group of cells is
afflicted by a disease while a neighboring group is not promises
to shed light on pathogenic causes. Although the logic of disease
localization has been validated—zooming in from anatomy to
cells and down to molecular mechanisms—it has only recently
been applied to complex disorders that affect the hippocampal
formation. Notably, the idea that the hippocampal formation is
a circuit made up of interconnected regions, each housing a
distinct group of neurons, was first suggested by Ramo´n y Cajal
(1911) (Figure 1), whose research was performed in the cell
theory spirit of the 19th century. (Indeed, compared to other
organs, the brain was the last holdout in defiance of cell theory.)
Subsequent cellular, electrophysiological, andmolecular studies32 Neuron 84, October 1, 2014 ª2014 Elsevier Inc.have further characterized the distinct properties of neurons
contained within each region of the hippocampal circuit—the en-
torhinal cortex, the dentate gyrus, the cornu ammonis (CA) sub-
fields, and the subiculum (Figure 1). Adding a further level of
complexity, the functional and molecular properties of neurons
within each region vary across the hippocampal long axis
(as reviewed in Small et al., 2011). This diversity within the hippo-
campal circuit accounts for how the circuit can be a ‘‘seat’’ to
a range of mechanistically distinct disorders. Its molecular diver-
sity, in particular, has led to the hypothesis that different regions
of the hippocampal circuit will be preferentially targeted by
different disorders (Small, 2001).
While a plausible hypothesis, pinpointing regional dysfunction
for many disorders that involve the hippocampal circuit presents
a challenge. Most disorders start subtly, in ‘‘preclinical’’ or
‘‘prodromal’’ stages that then worsen and spread over time,
somapping the anatomy of the earliest stages of disease is often
elusive by the time patients come to autopsy. Furthermore,
although some disorders develop dramatic cell death and other
clear histological findings, nearly all disorders begin in a ‘‘cell
sickness’’ stage—that is, neuronal dysfunction occurs before
neuronal loss. Mapping neuronal dysfunction using the time-
honored approach of postmortem examination is tricky.
In principle, in vivo functional imaging is well suited to over-
come these challenges, but it was only at the turn of the
21st century that MRI-based techniques began to be optimized,
enabling individual regions of the hippocampal circuit to be visu-
alized (Davachi and Wagner, 2002; Gabrieli et al., 1997; Kirwan
et al., 2007; Small et al., 1999, 2000, 2004; Zeineh et al., 2000).
Ultimately, by allowing the full circuit to be interrogated during
the earliest stages of diseases, these tools have been able to
localize hippocampal regions preferentially affected by—and,
just as important, resistant to—many disorders.
My colleagues and I have previously reviewed how the
anatomical organization of the hippocampal circuit provides a
Figure 1. Visualizing the Hippocampal
Circuit
In 1911, Ramo´n y Cajal used the Golgi-staining
technique applied to the postmortem rabbit
(left panel) to first show that regions of the
hippocampal formation comprise distinct neu-
rons and that the regions are connected to form
a circuit (Ramo´n y Cajal, 1911). Approximately
a hundred years later, functional imaging tech-
niques were optimized to visualize the regions of
the hippocampal circuit in living humans (middle
panel) and living mice (right panel). In the ex-
amples shown, fMRI images were generated
with an exogenous contrast agent allowing
submillimeter resolution (adapted from Khan
et al., 2014). LEC, lateral entorhinal cortex; MEC,
medial entorhinal cortex; DG, dentate gyrus;
SUB, subiculum.
Neuron
Perspectiveframework for characterizing and investigating hippocampal
dysfunction, among the surprisingly numerous and diverse
range of diseases that target this circuit (Small et al., 2011).
The primary purpose of this perspective is to review recent evi-
dence that illustrates how this framework has been successfully
applied in isolating pathogenic mechanisms. To date, the
clearest patterns of regional dysfunction within the hippocampal
circuit have been established for Alzheimer’s disease (AD),
schizophrenia, and cognitive aging, and it is for these disorders
that patterns of hippocampal dysfunction have been mechanis-
tically most illuminating.
It should be pointed out that other areas outside the hippo-
campal circuit are affected in all three disorders, and, as previ-
ously reviewed (Small et al., 2011), many are directly linked
to the circuit (for example, the posterior parietal lobe and the
precuneus in AD, the ventral striatum in schizophrenia, and the
prefrontal cortex in cognitive aging). My colleagues and I have
previously reviewed how connectivity with extrahippocampal
areas might account for phenotypic diversity among the range
of disorders in which the hippocampal circuit is implicated (Small
et al., 2011). In this perspective, with an eye on mechanism,
I focus exclusively on the hippocampal circuit and demonstrate
how the well-characterized organization of the circuit can be
used in an effort to follow the first principle of disease localiza-
tion. As I discuss here, by performing molecular studies de-
signed to address why one region of the circuit is affected and
another neighboring region is resistant to a particular disorder,
the circuit can be used as an anatomical ‘‘Rosetta stone’’ in
trying to decipher pathogenic mechanisms.
AD and Endosomal Transport
Although AD is a neurodegenerative disorder, it too is thought to
begin in a cell sickness stage (Selkoe, 2002), assumed to occur
years before cell death. Relying on various histological indicators
(Braak et al., 2006), but most compellingly on markers of cell
death (Go´mez-Isla et al., 1996), it has long been established
that the entorhinal cortex is the hippocampal region differentially
vulnerable to AD. The main contribution of neuroimaging has
been two-fold: first, a range of techniques have been able to
show that the entorhinal cortex is vulnerable to the AD even dur-ing its earliest preclinical stages (Huijbers et al., 2014; Khan et al.,
2014; Miller et al., 2013; Whitwell et al., 2007; Whitwell et al.,
2008). Second, fMRI studies in patients and animal models
have suggested that among all hippocampal regions, the
dentate gyrus is the one that is most resistant to the disease
(Moreno et al., 2007; Small et al., 2002), an observation that
has some postmortem support (West et al., 1994). Importantly,
functional neuroimaging has been able to detect entorhinal
cortex dysfunction in mouse models of disease (Khan et al.,
2014; Moreno et al., 2007), notable for manifesting cell sickness
without cell death, thereby validating that these neuroimaging
tools can in principle capture the earliest pathophysiological
stage of disease.
Guided by this pattern of dysfunction, my colleagues and I
performed amolecular profiling study on postmortem tissue har-
vested from the entorhinal cortex as the ‘‘target’’ region and the
dentate gyrus as the ‘‘within-subject control’’ region, from brains
with and without AD. A statistical model was used to identify
molecular correlates that might help explain why the entorhinal
cortex is targeted by AD but the neighboring dentate gyrus is
relatively preserved. Molecules linked to the retromer emerged
as the primary findings (Small et al., 2005). The retromer is an
assembly of proteins that work in unison to orchestrate cargo
transport out of endosomes (Burd and Cullen, 2014), either to
the trans-Golgi network or back to the cell surface. As originally
suggested (Small et al., 2005), retromer has been found to trans-
port the amyloid precursor protein (APP) out of endosomes
via VPS10-containing receptors—in particular, Sorl1 (also called
Sorla) (Fjorback et al., 2012). Although the Small et al. (2005)
study suggests that retromer defects are a molecular correlate
of entorhinal cortex dysfunction, they do not explain why these
defects occur in the entorhinal cortex in the first place. This
remains an outstanding question that my colleagues and I are
currently pursuing.
A pathogenic link to AD has been established by genetic
studies led by Richard Mayeux, Peter St. George-Hyslop, Lind-
say Farrer, and their colleagues. Collectively, these studies
have identified variants in SORL1 (Rogaeva et al., 2007), genes
encoding other VPS10-containing receptors (Reitz et al., 2013),
and genes encoding other key elements of retromer (VardarajanNeuron 84, October 1, 2014 ª2014 Elsevier Inc. 33
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confirmed by a recent large-scale genetic meta-analysis
(Lambert et al., 2013). Further support for a pathogenic role
has been provided by genetically modified retromer-deficient
animal models (Muhammad et al., 2008; Wen et al., 2011). It is
within endosomes that APP is most likely to be cleaved by
BACE1 (beta-site APP cleaving enzyme 1) (Small and Gandy,
2006), a b-secretase that initiates the ‘‘amyloidogenic’’ process-
ing of APP leading to the accumulation of the neurotoxic frag-
ments b-CTF (bC-terminal fragment) and Ab (amyloid b). Defects
in retromer-mediated transport lead to the accumulation of
these neurotoxic fragments by increasing the resident time of
APP in endosomes (Bhalla et al., 2012; Mecozzi et al., 2014).
The observed defects in the retromer transport pathway
should be interpreted in the context of a growing body of evi-
dence that has more broadly implicated endosomal transport
defects in the disease. Primary evidence pinpointing the endo-
some as the intracellular site of dysfunction was described in a
seminal series of histological studies performed by Randy Nixon
and his colleagues (Cataldo et al., 2000). They showed that
endosomes in the entorhinal cortex and the CA subfields of the
hippocampal circuit are abnormally enlarged during the earliest
stages of disease. Remarkably, the distribution of abnormally
enlarged endosomes was nearly diagnostic of the disease,
with very little overlap in the size of endosomes observed in
age-matched controls. Additionally, Nixon and colleagues
showed that carrying the APOE4 gene, the strongest genetic
risk factor for late-onset disease, further enhanced endosomal
enlargement and that abnormal enlargement did not occur as
part of normal aging. The near uniformity of the abnormality in
patients with late-onset ‘‘sporadic’’ AD suggests a convergence
of pathogenic mechanisms leading to endosomal enlargement.
Furthermore, enlarged endosomes are observed in brain re-
gions that were relatively free of evidence of Ab pathology (Cat-
aldo et al., 1997, 2000), which agrees with an emerging view
that endosomal abnormalities are upstream to Ab accumulation.
The fact that enlarged endosomes represent a cell-biological
phenotype of AD has recently been validated in neurons derived
via induced pluripotent stem cells (IPSCs) from patients (Israel
et al., 2012). Studies using IPSC-derived neurons have also
showed that APP mutations mistraffic APP to endosomes
(Muratore et al., 2014), an effect similar to that caused by retro-
mer defects.
Endosomes are a hub of membrane trafficking; mechanisti-
cally, it can be assumed that they become enlarged either
because of accelerated delivery, via cell-surface endocytosis,
or by reducing the transport out of endosomes. Indeed, Nixon
and his colleagues provided the first evidence for increased
endocytosis in AD (Cataldo et al., 1997), while retromer defects
(Bhalla et al., 2012) and an AD-associated deficiency in phos-
phatidylinositol-3-phosphate (Morel et al., 2013), a lipid that
regulates transport of cargo out of endosomes, cause enlarged
endosomes. Interestingly, one of many effects of APOE4 is the
increase of the endocytosis of cargo including APP from the
surface membrane (Ye et al., 2005; Yu et al., 2014), which can
explain why APOE4 is associated with enlarged endosomes.
More generally, additional evidence that endosomal dysfunction
plays an upstream role in AD pathology comes from large-scale34 Neuron 84, October 1, 2014 ª2014 Elsevier Inc.genetic studies that have identified a group of endosomal trans-
port genes that have emerged as a unified genetic factor linked
to AD (Lambert et al., 2013).
Besides accounting for how APP fragments can be mispro-
cessed in late onset AD, recent studies are beginning to link en-
dosomal transport defects to other core features of the disease.
For example, retromer defects have been found in microglia of
AD patients (Lucin et al., 2013), and this same study showed
how these defects reduce the cell surface transport of AD-linked
microglia receptors. Of course, besides amyloid accumulation,
neurofibrillary tangles and their constituent abnormal tau species
are the second defining histological feature of AD. While amyloid
accumulation—particularly, its soluble forms (Lue et al., 1999;
Na¨slund et al., 2000)—begins to accumulate in the entorhinal
cortex during the early disease stages, tau-related abnormalities
are very prominent histological features found in this region.
Might endosomal dysfunction be linked to tau toxicity? This re-
mains an open question, but recent evidence suggests that the
processing to tau pathology is triggered while tau is translocated
to endosomes (Michel et al., 2014). Additionally, recent studies
have begun finding associations of AD-linked endosomal genes
with tau pathology (Ando et al., 2013; Chapuis et al., 2013).
Taken together, these observations establish that endosomal
dysfunction is a pathogenic mechanism and validate endosomal
transport as a ‘‘cell-biological’’ target for drug discovery.
Providing proof of principle for this idea, in collaboration with
Greg Petsko and Dagmar Ringe, my colleagues and I have
recently isolated a novel class of pharmacological chaperones
(Mecozzi et al., 2014) that increases the stability and function
of retromer, shunts APP away from endosomes, and decreases
the abnormal processing of APP. In principle, there are
numerous other pharmacological approaches that can correct
endosomal transport defects, and future studies will determine
whether these novel classes of drugs will prove efficacious
when applied to the early stages of AD.
Schizophrenia and Glutamate Production or Catabolism
In schizophrenia, in contrast with AD, the histological abnormal-
ities observed within the hippocampal circuit are subtler, primar-
ily involving a mild loss of GABAergic interneurons in the CA
regions (Benes and Berretta, 2001) (Figure 2). Neuroimaging
has, therefore, played a more important role in implicating
the hippocampal circuit in the disease. This was originally docu-
mented using relatively low-resolution techniques, showing
dominant hippocampal atrophy in the disease (as reviewed
in Adriano et al., 2012), and in studies suggesting that that the
hippocampus is characterized by an abnormal hypermetabolic
state (Friston et al., 1992; Heckers et al., 1998; Kawasaki et al.,
1992; Malaspina et al., 2004; Medoff et al., 2001; Schobel et al.,
2009). A recent study, combining high-resolution functional and
structural MRI applied to patients in the earliest stages of the
disease, more precisely mapped the spatial and temporal profile
of abnormalities within the hippocampal circuit (Schobel et al.,
2013). These studies suggest that hypermetabolism occurs first,
observed during prodromal stages, and is localized to the CA1
region of the hippocampal circuit. With progression to the psy-
chosis stageof disease, hypermetabolism is followedbyatrophy,
and this too is localized predominantly to the CA1 (Figure 2).
Figure 2. Pathogenic Mechanisms and the
Progression of Hippocampal-Based
Disorders
AD starts in a preclinical stage before progressing
to dementia. Hypometabolism during the preclin-
ical stage has been localized to the entorhinal
cortex (EC), in which defects in retromer-mediated
endosomal transport have been isolated. Schizo-
phrenia starts in a prodromal stage before pro-
gressing to psychosis. Hypermetabolism during
the prodromal stage has been localized to the
CA1 region and has been linked to increases in
extracellular glutamate. Cognitive aging starts
in the fourth decade of life and progresses
gradually to memory decline. Hypometabolism
during normal aging has been localized to the
dentate gyrus (DG), in which defects in CREB-
dependent histone acetylation have been isolated.
During the progression of each entity, a primary
cell sickness stage is thought to antedate a cell
death stage (a dramatic loss of primary neurons
in AD, a more subtle loss of GABAergic interneurons in schizophrenia, and a subtle loss of hilar interneurons in cognitive aging). Accordingly, the disorders
are anticipated to be most amenable to therapeutic interventions during the earliest pathophysiological stage.
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permetabolism drives the ensuing atrophy, and it was hypothe-
sized that elevations in extracellular glutamate might act as the
pathogenic driver of both indicators of hippocampal dysfunction
(Schobel et al., 2013). This hypothesis was based on the fact that
NMDA-blocking agents, which cause an increase in extracellular
glutamate (Moghaddam et al., 1997), recapitulate the disease’s
full spectrum of symptoms (Krystal et al., 1994) and because
mouse fMRI studies suggested that the CA1 region is differen-
tially sensitive to alterations in glutamate (Gaisler-Salomon
et al., 2009). This hypothesis was confirmed when the same
high-resolution fMRI and structural MRI techniques were
applied to mice that were administered NMDA-blocking
agents (Schobel et al., 2013). These studies established that
elevations in extracellular glutamate phenocopied the disease,
first causing selective CA1 hypermetabolism followed more
slowly by atrophy. Furthermore, the MRI-detected atrophy
was shown to be associated with GABAergic interneuron loss,
thereby phenocopying the histological findings of the disease
(Schobel et al., 2013). This interpretation is bolstered by a recent
study combining magnetic resonance spectroscopy (MRS) and
structural MRI (Kraguljac et al., 2013), showing that glutamate
elevations in the hippocampus of patients are correlated with
CA1 atrophy.
What then causes the elevations in extracellular glutamate?
One idea is that there is a relative redistribution of glutamate
from the intracellular to the extracellular space. This interpreta-
tion might be problematic, however, because the glutamate
elevations observed by MRS cannot be caused by a simple
redistribution of glutamate. Rather, these neuroimaging findings
suggest that there is a net increase in glutamate levels, either by
increased production or by decreased catabolism. The produc-
tion and catabolism of glutamate is tightly regulated by a group
of enzymes distributed in astrocytes and neurons (Erecinska
and Silver, 1990; Maciejewski and Rothman, 2008)—including
glutamate dehydrogenase; glutaminase; glutamine synthetase;
glutamic acid decarboxylase; GABA transaminase; and aspar-
tate and alanine aminotransferases. It is hypothesized, therefore,that these enzymes might be defective in schizophrenia. Alter-
ations in this group of enzymes might occur genetically, either
directly, by genes encoding these enzymes (Jia et al., 2010);
secondarily, by genetic links to the glutamatergic system (Walsh
et al., 2008; Wilson et al., 2006; Winchester et al., 2014) or via
environmental stressors and risk factors (e.g., Matrisciano
et al., 2012). Alternatively, alternations in this group of enzymes
might occur via environmental stressors.
Although this hypothesis awaits further confirmation, the
imaging studies summarized earlier suggest that glutamate
elevation itself is a valid drug target and that glutamate-reducing
agents might be an effective therapeutic intervention. An impor-
tant implication of the imaging studies is that these agents
should be given during prodromal stages of disease, before
the loss of interneurons and its imaging correlate atrophy
(Figure 2). Indeed, recent failures of clinical trials using the gluta-
mate-reducing agent pomaglumetad methionil (LY2140023
monohydrate) (Adams et al., 2014) might be explained by the
fact that they were tested in patients who were already in
advanced stages of the disease.
Cognitive Aging and CREB-Dependent Histone
Acetylation
Perhapsmore than any other process that targets the hippocam-
pal circuit, mapping the effects of normal aging is most chal-
lenging, as there are a number of diseases that target the aging
hippocampal circuit, including AD, vascular disease, and dia-
betes (Wu et al., 2008). Insofar that it is still difficult to completely
exclude these disorders when investigating the hippocampal
circuit in aging populations, isolating an anatomical pattern of
dysfunction linked to aging per se presents a unique challenge.
One approach in addressing this challenge is to apply high-
resolution fMRI tools in a comparative cross-species manner.
The hippocampal circuit is remarkably homologous across
mammals (Figure 1), and all develop age-related hippocampal
dysfunction. As nonhuman mammals do not develop AD,
vascular disease, or diabetes, it is assumed that mechanisms
by which aging affects the hippocampal circuit are preserved,Neuron 84, October 1, 2014 ª2014 Elsevier Inc. 35
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then patterns of age-related regional dysfunction should also
be preserved. Guided by this reasoning, my colleagues and I
have first applied high-resolution fMRI tools to healthy humans
across the life span (Small et al., 2002) and then tested whether
these patterns are observed in aging rhesus monkeys (Small
et al., 2004), rats, and wild-type mice (Moreno et al., 2007).
Together, these results have suggested that the dentate gyrus
is the dominant region affected by aging, while the entorhinal
cortex is the region that shows the greatest resistance. Notably,
dentate gyrus dysfunction appears to begin in the fourth decade
of life and to worsen gradually thereafter (Figure 2).
Other studies using alternative forms of fMRI (Yassa et al.,
2011b) or structural MRI (Wisse et al., 2014) largely agree with
this conclusion, and in fact some studies suggest that aging is
associated with a mild loss of interneurons selectively in the
dentate gyrus (West, 1993). With a greater appreciation of the
distinct cognitive operations performed by the dentate gyrus—
notably, pattern separation (Yassa and Stark, 2011)—memory
tests have been developed that can assess dentate gyrus
function using cognitive measures. By applying these cognitive
tools, a growing number of studies have confirmed that the
dentate gyrus is a dominant ‘‘seat’’ of age-related hippocampal
dysfunction (Gracian et al., 2013; Holden et al., 2012; Yassa
et al., 2011a).
Guided by this pattern of dysfunction, my colleagues and I
performed a molecular profiling study on postmortem tissue
harvested from the dentate gyrus as the target region and the
entorhinal cortex as the within-subject control region from
healthy brains across the adult life span (Pavlopoulos et al.,
2013). A statistical model was used to identify molecular corre-
lates that might help explain why the dentate gyrus is targeted
by aging, but the neighboring entorhinal cortex is relatively pre-
served. Results implicated the histone-binding protein RbAp48
(Pavlopoulos et al., 2013), which was found to undergo selective
age-related deficiency in the dentate gyrus. By interacting with
the cAMP Response Element-Binding Protein (CREB)-Binding
Protein (CBP) (Zhang et al., 2000), RbAp48 regulates CREB-
dependent histone acetylation and transcription. In a collabo-
rative study with Eric Kandel (Pavlopoulos et al., 2013), my
colleagues and I first confirmed that RbAp48 is, as in humans,
selectively deficient in the dentate gyrus of aging wild-type
mice. More important, Kandel’s lab developed a mouse model
that expressed a dominant-negative inhibitor of RbAp48. These
mice were found to phenocopy the cognitive, neuroimaging,
and histone acetylation defects characteristic of the aging
hippocampal circuit. Providing further causal confirmation, over-
expressing RbAp48 selectively in the dentate gyrus of aging
wild-type mice rescued age-related memory decline (Pavlopou-
los et al., 2013).
Another recent study provided further causal confirmation
that the dentate gyrus is the seat of age-related memory decline
and for its underlying molecular mechanism (Villeda et al., 2014).
This study used heterochronic parabiosis to transfer the blood
of young mice to old mice. Young blood was found to rescue
the electrophysiological and behavior phenotypes of the aging
hippocampus, and it did so by increasing spine density selec-
tively in the dentate gyrus. Moreover, the induced increase in36 Neuron 84, October 1, 2014 ª2014 Elsevier Inc.dentate gyrus spine density was found to be mediated by the
CREB pathway.
Perhaps the strongest pathogenic link between CREB-depen-
dent histone acetylation and cognitive aging in humans comes
from a recent genetic study performed by Richard Mayeux and
his colleagues (Barral et al., 2014). They tested whether variants
in genes encoding RbAp48, CREB1, and CBP are associated
with memory performance in cognitively healthy elderly humans.
While associations were detected in variants encoding all three
proteins, the strongest and most reliable association was for
variants encoding CBP (Barral et al., 2014).
These findings suggest interventions for ameliorating age-
related memory decline. While age-related memory decline is,
to some degree, universal and, therefore, has extremely high
prevalence, the symptoms associated with aging are not nearly
as devastating as those caused by disease. Nevertheless, with
increasing longevity, even mild memory decline has a negative
impact on older individuals who are not only living longer but
who want to remain engaged in cognitively demanding lifestyles.
There is a pharmacopeia of agents that target the CREB
pathway, and these might be worth testing in aging populations.
Indeed, the U.S. Food and Drug Administration has recently
opined that age-related memory decline is an approved indica-
tion for clinical trials. At the same time, because age-related
memory decline is considered a normal process, behavioral or
dietary interventions might be more appropriate. Aerobic exer-
cise is one such intervention, as neuroimaging studies have
found that it enhances dentate gyrus function (Pereira et al.,
2007). Dietary interventions might also work, as Fred Gage and
his colleagues have shown that a diet enriched in the flavanol
epicatechin improves dentate gyrus function in mice (van Praag
et al., 2007). Accordingly, we have initiated a randomized
controlled clinical trial, testing the effect that a high flavanol
diet has on the hippocampal circuit in healthy aging individuals.
Conclusions
Giovanni Morgagni was quoted as saying that, when presented
with a disease, one should listen to the ‘‘cry of a suffering organ.’’
With the introduction of cell theory and its clinical correlate,
cellular pathology, listening needed to be fine tuned to detect
the cry of suffering cells. High-resolution fMRI and structural
MRI have turned out to be very good listening devices that can
isolate the group of neurons preferentially afflicted by, and rela-
tively resistant to, various disorders that target the hippocampal
circuit. Moreover, neuroimaging studies have, de novo, estab-
lished or reaffirmed that disorders can start in a cell sickness
stage before progressing to cell death, a later stage that must
be considered more intractable to therapeutic interventions
(Figure 2).
While these neuroimaging tools might be useful in improving
diagnostic capabilities, disease localization is most important
for isolating pathogenic mechanisms. As reviewed in this
Perspective, insight into cellular pathophysiology and molecular
mechanisms can be used to develop novel interventions. Human
genetics or animal models have at least partially validated
many of the mechanisms discussed. Nevertheless, the ultimate
validation of any hypothesis about disease is showing that an
intervention that targets the proposed cellular site or molecular
Neuron
Perspectivemechanism treats the actual disease. This ultimate validation
awaits future studies for all disorders that affect the hippocampal
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